Drug companies that manufacture ketamine are expected to lead profits in the category, according to an Anesthesia Drug Market study. Ketalar, distributed by JHP Pharmaceuticals, is currently the only branded version of the drug offered on the market.
Ketalar is expected to maintain a high profile in the market over the next five years, according to the study, but could see a drop in sales due to an increasing demand for less expensive generic counterparts.
Related Articles on Anesthesiology:
Two Anesthesiologists Selected to Lead St. Joseph Medical Center Anesthesia Department
Anesthesiologist Receives American Pain Society Award
Anesthesiologist Elected to Massachusetts Medical Society House of Delegates
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
